Hepatic Krüppel‐like factor 14 regulates lipid metabolism in nonalcoholic steatohepatitis mice

Excessive lipid accumulation is a critical characteristic in the development of nonalcoholic steatohepatitis (NASH). The underlying molecular mechanism, however, is unclear. In this study, we explored whether and how Krüppel‐like factor 14 (KLF14) affects hepatic lipid metabolism in NASH. KLF14 expression was detected in NASH patients and mice fed a choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD). Adeno‐associated viruses and adenoviruses were used to alter hepatic KLF14 expression in vivo or in vitro to investigate how KLF14 functions in lipid regulation. The molecular mechanisms were explored using RNA‐seq, luciferase reporter, and ChIP assays. The fatty liver phenotype was analyzed histopathologically, and serum and hepatocyte biochemical parameters were measured. The NASH mouse model developed quickly in C57BL/6J mice fed a CDAHFD for 8 weeks. We found that KLF14 expression was decreased in NASH patients and CDAHFD mice. Oleic acid and palmitic acid treatment also reduced KLF14 levels in hepatocytes. KLF14 knockdown downregulated the genes involved in fatty acid oxidation, promoting the progression of hepatic steatosis. In contrast, hepatic KLF14 overexpression alleviated lipid accumulation and oxidative stress in CDAHFD mice. These effects resulted from direct activation of the PPARα signaling pathway. PPARα inhibition diminished the KLF14 overexpression‐reduced protective effects against steatosis in OA&PA‐treated MPHs and AAV‐KLF14‐infected CDAHFD mice. These data reveal that hepatic KLF14 regulates lipid accumulation and oxidative stress through the KLF14‐PPARα pathway as NASH progresses. KLF14 may be a novel therapeutic target for hepatic steatosis.

[1]  K. Cusi,et al.  A global view of the interplay between non-alcoholic fatty liver disease and diabetes. , 2022, The lancet. Diabetes & endocrinology.

[2]  Weixuan Wang,et al.  Breviscapine alleviates NASH by inhibiting TGF‐β‐activated kinase 1‐dependent signaling , 2021, Hepatology.

[3]  Shaoping Huang,et al.  Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction. , 2021, The Journal of nutritional biochemistry.

[4]  H. Tilg,et al.  Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. , 2021, The lancet. Gastroenterology & hepatology.

[5]  P. Caravan,et al.  Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis , 2021, Scientific Reports.

[6]  Y. E. Chen,et al.  Krüppel-Like Factor 14 Deletion In Myeloid Cells Accelerates Atherosclerotic Lesion Development. , 2021, Cardiovascular research.

[7]  Yongsheng Chang,et al.  Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance , 2020, Gut.

[8]  K. Miyashita,et al.  Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice. , 2020, Biochemical and biophysical research communications.

[9]  B. Neuschwander‐Tetri Therapeutic landscape for NAFLD in 2020. , 2020, Gastroenterology.

[10]  Heng Zhang,et al.  The role of KLF14 in multiple disease processes , 2020, BioFactors.

[11]  Xi-Long Zheng,et al.  Krüppel-like factor 14 inhibits atherosclerosis via mir-27a-mediated down-regulation of lipoprotein lipase expression in vivo. , 2019, Atherosclerosis.

[12]  T. Uchida,et al.  Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice. , 2019, Life sciences.

[13]  Wei Ma,et al.  Dexamethasone-induced Krüppel-like factor 9 expression promotes hepatic gluconeogenesis and hyperglycemia. , 2019, The Journal of clinical investigation.

[14]  H. Hermanns,et al.  Animal models of NAFLD from a hepatologist's point of view. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[15]  T. Ishikawa,et al.  Vitronectin deficiency attenuates hepatic fibrosis in a non‐alcoholic steatohepatitis‐induced mouse model , 2019, International journal of experimental pathology.

[16]  Z. Younossi Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[17]  F. Tacke,et al.  Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism , 2019, JHEP reports : innovation in hepatology.

[18]  Xiaoyan Chen,et al.  Overexpression of KLF14 protects against immune-mediated hepatic injury in mice , 2018, Laboratory Investigation.

[19]  Andrew R. Hall,et al.  CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. , 2018, Journal of hepatology.

[20]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[21]  O. Ilkayeva,et al.  Kruppel-like factor 15 is required for the cardiac adaptive response to fasting , 2018, PloS one.

[22]  M. Eslam,et al.  Genetics and epigenetics of NAFLD and NASH: Clinical impact. , 2018, Journal of hepatology.

[23]  Huabing Zhang,et al.  The KLF14 transcription factor regulates hepatic gluconeogenesis in mice , 2017, The Journal of Biological Chemistry.

[24]  Huabing Zhang,et al.  KLF10 transcription factor regulates hepatic glucose metabolism in mice , 2017, Diabetologia.

[25]  P. He,et al.  SP and KLF Transcription Factors in Digestive Physiology and Diseases. , 2017, Gastroenterology.

[26]  Jun Yu,et al.  Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances , 2016, The Journal of pathology.

[27]  Y. Rotman,et al.  Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease , 2016, Gut.

[28]  Tingting Zhou,et al.  Krüppel-like factor 14 increases insulin sensitivity through activation of PI3K/Akt signal pathway. , 2015, Cellular signalling.

[29]  D. Rader,et al.  Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. , 2015, The Journal of clinical investigation.

[30]  Douglas A. Simonetto,et al.  New Role for Kruppel-like Factor 14 as a Transcriptional Activator Involved in the Generation of Signaling Lipids* , 2014, The Journal of Biological Chemistry.

[31]  S. Kersten Integrated physiology and systems biology of PPARα , 2014, Molecular metabolism.

[32]  Saptarsi M. Haldar,et al.  Kruppel-like Factor 15 Is a Critical Regulator of Cardiac Lipid Metabolism* , 2014, The Journal of Biological Chemistry.

[33]  D. Hum,et al.  Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.

[34]  Marie-Pier Tétreault,et al.  Krüppel-like factors in cancer , 2013, Nature Reviews Cancer.

[35]  Min Wang,et al.  Mouse KLF11 regulates hepatic lipid metabolism. , 2013, Journal of hepatology.

[36]  C. Tanaka,et al.  An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis , 2013, International journal of experimental pathology.

[37]  L. Jin,et al.  Genome‐wide association study validation identifies novel loci for atherosclerotic cardiovascular disease , 2012, Journal of thrombosis and haemostasis : JTH.

[38]  Jiansheng Huang,et al.  Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  T. Spector,et al.  Corrigendum: Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes , 2011, Nature Genetics.

[40]  Mark I. McCarthy,et al.  Identification of an imprinted master trans-regulator at the KLF14 locus related to multiple metabolic phenotypes , 2011, Nature Genetics.

[41]  F. Gonzalez,et al.  PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. , 2011, The Journal of nutrition.

[42]  V. Yang,et al.  Mammalian Krüppel-like factors in health and diseases. , 2010, Physiological reviews.

[43]  R. Urrutia,et al.  Sp1- and Krüppel-like transcription factors , 2003, Genome Biology.

[44]  Xiaobin Pang,et al.  Luteoloside attenuates neuroinflammation in focal cerebral ischemia in rats via regulation of the PPAR&ggr;/Nrf2/NF‐&kgr;B signaling pathway , 2019, International immunopharmacology.

[45]  A. Diehl,et al.  Animal Models of Nonalcoholic Fatty Liver Disease , 2016 .

[46]  Jack A. Taylor,et al.  Supplementary file 1. , 2014 .

[47]  Joseph P. Near,et al.  How to cite this article , 2011 .

[48]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.